(Q53676680)

17 May 2018

http://europepmc.org/abstract/MED/22280056

title

Pharmacokinetics and Pharmacodynamics of Pegylated Interferon Lambda-1 in Cynomolgus Monkeys (English)

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

23 December 2024

1 reference

1 reference

1 reference

1

Kelly A. Byrnes-Blake

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22280056

23 December 2024

author name string

Susan Pederson

2

1 reference

17 May 2018

http://europepmc.org/abstract/MED/22280056

Monica Anderson-Haley

4

1 reference

17 May 2018

http://europepmc.org/abstract/MED/22280056

Juan Carlos Lopez-Talavera

6

1 reference

17 May 2018

http://europepmc.org/abstract/MED/22280056

Kevin M. Klucher

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22280056

23 December 2024

Dennis M. Miller

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22280056

23 December 2024

Jeremy A. Freeman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22280056

23 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22280056

23 December 2024

publication date

26 January 2012

1 reference

17 May 2018

http://europepmc.org/abstract/MED/22280056

full work available at URL

http://www.liebertpub.com/doi/full-xml/10.1089/jir.2011.0075

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

http://www.liebertpub.com/doi/pdf/10.1089/jir.2011.0075

23 December 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Journal of Interferon and Cytokine Research

23 December 2024

published in

1 reference

17 May 2018

http://europepmc.org/abstract/MED/22280056

volume

32

1 reference

17 May 2018

http://europepmc.org/abstract/MED/22280056

issue

5

1 reference

17 May 2018

http://europepmc.org/abstract/MED/22280056

page(s)

198-206

1 reference

17 May 2018

http://europepmc.org/abstract/MED/22280056

cites work

Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo

1

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Reviews in gastroenterological disorders

23 December 2024

2

1

87

Baker DE

2001

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Comparison of pharmacokinetic behaviors of two human interferons (Lb-IFN-alpha and Re-IFN-alpha A) in cynomolgus monkeys by 2'-5' oligoadenylate synthetase assay

23 December 2024

3

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates

23 December 2024

5

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans

23 December 2024

6

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Physiological parameters in laboratory animals and humans

23 December 2024

7

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

The type-I interferon receptor. The long and short of it.

23 December 2024

8

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain

23 December 2024

9

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes

23 December 2024

10

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling

23 December 2024

11

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases

23 December 2024

12

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Interferons in Host Defense

23 December 2024

13

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b

23 December 2024

14

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma

23 December 2024

15

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Virus interference. I. The interferon

23 December 2024

16

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

The family of IL-10-related cytokines and their receptors: related, but to what extent?

23 December 2024

17

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

23 December 2024

18

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes

23 December 2024

19

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C.

23 December 2024

20

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys

23 December 2024

21

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity

23 December 2024

22

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

23 December 2024

23

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Interferon lambda as a potential new therapeutic for hepatitis C.

23 December 2024

24

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

23 December 2024

25

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys

23 December 2024

26

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

The interferons: 50 years after their discovery, there is much more to learn

23 December 2024

28

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Interferons, interferon-like cytokines, and their receptors

23 December 2024

29

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Interferons and their actions

23 December 2024

30

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Role of the cytoplasmic domains of the type I interferon receptor subunits in signaling

23 December 2024

31

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C.

23 December 2024

32

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

IL-28, IL-29 and their class II cytokine receptor IL-28R

23 December 2024

33

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo

23 December 2024

34

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates

23 December 2024

35

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines

23 December 2024

36

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases

23 December 2024

37

1 reference

https://api.crossref.org/works/10.1089/JIR.2011.0075

23 December 2024

Identifiers

1 reference

17 May 2018

http://europepmc.org/abstract/MED/22280056

1 reference

17 May 2018